[go: up one dir, main page]

MX2019009418A - Formulaciones de combinacion del triplete y metodos para tratar o reducir el riesgo de enfermedad cardiovascular. - Google Patents

Formulaciones de combinacion del triplete y metodos para tratar o reducir el riesgo de enfermedad cardiovascular.

Info

Publication number
MX2019009418A
MX2019009418A MX2019009418A MX2019009418A MX2019009418A MX 2019009418 A MX2019009418 A MX 2019009418A MX 2019009418 A MX2019009418 A MX 2019009418A MX 2019009418 A MX2019009418 A MX 2019009418A MX 2019009418 A MX2019009418 A MX 2019009418A
Authority
MX
Mexico
Prior art keywords
methods
cardiovascular disease
risk
treat
reduce
Prior art date
Application number
MX2019009418A
Other languages
English (en)
Inventor
LALWANI Narendra
MACDOUGALL Diane
Original Assignee
Esperion Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Esperion Therapeutics Inc filed Critical Esperion Therapeutics Inc
Publication of MX2019009418A publication Critical patent/MX2019009418A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a composiciones que comprenden ETC-1002; Ezetimiba; una estatina; y uno o más excipientes o portadores farmacéuticos. También se describen en la presente métodos para usar tal composición. Los usos incluyen métodos para tratar la enfermedad cardiovascular o reducir el riesgo de enfermedad cardiovascular en un sujeto. Los usos también incluyen métodos para tratar hipercolesterolemia y/o dislipidemias en un sujeto.
MX2019009418A 2017-02-08 2018-02-08 Formulaciones de combinacion del triplete y metodos para tratar o reducir el riesgo de enfermedad cardiovascular. MX2019009418A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762456571P 2017-02-08 2017-02-08
PCT/US2018/017434 WO2018148417A1 (en) 2017-02-08 2018-02-08 Triplet combination formulations and methods of treating or reducing the risk of cardiovascular disease

Publications (1)

Publication Number Publication Date
MX2019009418A true MX2019009418A (es) 2019-10-02

Family

ID=63107115

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019009418A MX2019009418A (es) 2017-02-08 2018-02-08 Formulaciones de combinacion del triplete y metodos para tratar o reducir el riesgo de enfermedad cardiovascular.

Country Status (9)

Country Link
US (1) US20210361618A1 (es)
EP (2) EP3579827A4 (es)
JP (2) JP2020506241A (es)
CN (1) CN110536684A (es)
BR (1) BR112019016307A2 (es)
CL (2) CL2019002218A1 (es)
IL (1) IL268502A (es)
MX (1) MX2019009418A (es)
WO (1) WO2018148417A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107530307A (zh) 2015-03-13 2018-01-02 艾斯柏伦治疗公司 包含etc1002和依泽替米贝的固定剂量组合和制剂以及治疗心血管疾病或降低心血管疾病风险的方法
BR112019016307A2 (pt) 2017-02-08 2020-03-31 Esperion Therapeutics, Inc. Formulações de combinação de tripleto e métodos para tratar ou reduzir o risco de doença cardiovascular
CA3110346A1 (en) * 2018-08-24 2020-02-27 Esperion Therapeutics, Inc. Methods for reducing the risk of diabetes in patients being treated for high cholesterol-related illnesses
US20210322375A1 (en) * 2018-08-27 2021-10-21 Esperion Therapeutics, Inc. Combination drug formulations for treating patients with cardiovascular disease and associated conditions
PH12021552553A1 (en) 2019-04-16 2022-06-20 Celagenex Res India Pvt Ltd Synergistic lipid controlling compositions
BR112021025928A2 (pt) 2019-06-21 2022-05-10 Esperion Therapeutics Inc Métodos de preparação de ácido bempedoico e composições do mesmo
CN113133997B (zh) * 2020-01-20 2024-02-09 深圳市长卿医学研究院 一种含小檗碱的药物组合物及其用途
CN113134086B (zh) * 2020-01-20 2024-05-24 深圳市长卿医学研究院 一种降血脂的药物组合物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006109170A2 (en) * 2005-04-14 2006-10-19 Esperion Therapeutics Inc. Combination therapy for treatment of cardiovascular diseases and related conditions
CA2861643C (en) * 2012-01-06 2020-10-06 Charles L. Bisgaier Methods of reducing risk of cardiovascular disease
US9255154B2 (en) * 2012-05-08 2016-02-09 Alderbio Holdings, Llc Anti-PCSK9 antibodies and use thereof
GB201318793D0 (en) * 2013-10-24 2013-12-11 Plaquetec Ltd Vascular Biomarkers
CN107530307A (zh) * 2015-03-13 2018-01-02 艾斯柏伦治疗公司 包含etc1002和依泽替米贝的固定剂量组合和制剂以及治疗心血管疾病或降低心血管疾病风险的方法
MA41793A (fr) * 2015-03-16 2018-01-23 Esperion Therapeutics Inc Associations de doses fixes comprenant du etc1002 et une ou plusieurs statines permettant de traiter ou de réduire un risque cardiovasculaire
BR112019016307A2 (pt) 2017-02-08 2020-03-31 Esperion Therapeutics, Inc. Formulações de combinação de tripleto e métodos para tratar ou reduzir o risco de doença cardiovascular

Also Published As

Publication number Publication date
JP7716437B2 (ja) 2025-07-31
JP2020506241A (ja) 2020-02-27
EP4461295A3 (en) 2025-01-15
IL268502A (en) 2019-09-26
US20210361618A1 (en) 2021-11-25
CL2021002447A1 (es) 2022-04-22
BR112019016307A2 (pt) 2020-03-31
WO2018148417A1 (en) 2018-08-16
CN110536684A (zh) 2019-12-03
EP4461295A2 (en) 2024-11-13
CL2019002218A1 (es) 2020-02-21
EP3579827A1 (en) 2019-12-18
JP2023040237A (ja) 2023-03-22
EP3579827A4 (en) 2021-01-06

Similar Documents

Publication Publication Date Title
MX2019009418A (es) Formulaciones de combinacion del triplete y metodos para tratar o reducir el riesgo de enfermedad cardiovascular.
CL2021001292A1 (es) Terapia de combinación que incluye un inhibidor de krasg12c y uno o más agentes farmacéuticamente activos adicionales para el tratamiento de cánceres
CO2019009423A2 (es) Inhibidores de mnk sustituidos con piperidina y métodos relacionados con los mismos
ECSP20020410A (es) Inhibidores de la ectonucleótido pirofosfatasa-fosfodiesterasa 1 (enpp-1) y usos de los mismos
CL2018001152A1 (es) Composiciones y métodos para el tratamiento del cáncer
CL2020002624A1 (es) Formulaciones de inmunoconjugado anti-cd79b estables.
CR20190318A (es) Compuestos heterocíclicos como inmunomoduladores
ECSP19078393A (es) Compuestos inhibidores de ask1 y usos de los mismos
PH12020551427A1 (en) Epinephrine spray formulations
MX2018007774A (es) Compuestos heterociclicos como inmunomoduladores.
BR112016020199A8 (pt) composto inibidor de calicreína plasmática de humano, composição farmacêutica compreendendo o referido composto, kit e seu uso
MX2024008886A (es) Sulfonamida sustituida con trifluorometilo como inhibidor selectivo de bcl-2.
CO2019009722A2 (es) Dendrímeros terapéuticos
AR107871A1 (es) Combinaciones de inhibidores de lsd1 para su uso en el tratamiento de tumores sólidos
CL2017002334A1 (es) Combinaciones y formulaciones de dosis fijas que comprenden etc-1002 y una o más estatinas y métodos para tratar o reducir el riesgo de enfermedad cardiovascular
CO2017003838A2 (es) Compuestos de aminopurina sustituida, composiciones del mismo, y métodos de tratamiento con los mismos
PE20181165A1 (es) Derivados de indol mono-o disustituidos como inhibidores de la replicacion viral del dengue
CL2017002299A1 (es) Combinaciones de dosis fija y formulaciones comprendiendo etc-1002 y ezetimiba y métodos para tratar o reducir el riesgo de enfermedades cardiovasculares
MX2018013164A (es) Compuestos novedosos de imidazopiridina sustituida como inhibidores de indolamina-2,3-dioxigenasa y/o triptofano-2,3-dioxigenasa.
CL2020000270A1 (es) Combinación terapéutica de un inhibidor tirosina quinasa del egfr de tercera generación y un inhibidor raf.
MX2021000542A (es) Apirasas solubilizadas, metodos y usos.
CL2018000430A1 (es) Compuesto de hidroxitriazina y uso médico relacionado.
CL2017002229A1 (es) Inhibidores de bace1.
MX2021006654A (es) Uso de extracto de cocculus hirsutus para tratar dengue.
MX2018010707A (es) Métodos y composiciones para el tratamiento de la infección por el virus del zika.